The T α 1 peptide can be administered via subcutaneous injection or as a transdermal cream. T α 1 has been found to be very safe, and there have not been any documented side effects associated with its administration. It is approved in more than 37 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to chemotherapy and various vaccines.

Nevertheless, the hypothesis that AOD9604 does not activate the hGH/IGF-1 axis had to be tested in humans. The studies presented here confirm the in-vitro results. In these studies no clinically relevant changes of IGF-1 levels were observed and no differences to the placebo treatment were found. Together with the lack of any other symptoms associated with known IGF-1 mediated effects, such as sodium retention, tissue oedema, hypertension, or impaired glucose tolerance, the results demonstrate that AOD9604 does not activate the hGH/IGF-1 pathway and therefore has no growth promoting effect.
SARMs are selective androgen receptor modulators. Androgens are naturally occurring hormones—such as testosterone—that regulate the development and maintenance of male sex characteristics. SARMs provide the benefits of anabolic steroids (i.e., increased muscle mass/strength, fat loss, increased bone density, increased libido) without the quantity and/or severity of unwanted effects. SARMs are not toxic to the liver, separating them from most oral steroids and making them an attractive treatment option to those looking to benefit from anabolic steroid drugs.
Several epidemiologic studies have reported lower circulating natriuretic peptide concentrations in obese individuals.12, 14 However, these studies have been observational and confined to a single time point of measurement of natriuretic peptides. To our knowledge, only one previous study has examined the association of obesity with salt‐induced natriuretic peptide concentrations. Licata and colleagues found reduced, salt‐loaded plasma ANP concentrations in 9 obese individuals compared with 10 lean controls.21 They did not examine the influence of weight loss on the natriuretic peptide system. Thus, the present study is the first to provide serial, physiologic data from the same individuals over time.
CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with theβ -adrenergic pathway, particularly with theβ 3-adrenergic receptors (β3-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression ofβ 3-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of β3-AR RNA in obese mice to levels comparable with those in lean mice. The importance ofβ 3-AR was verified when long-term treatment with hGH and AOD9604 in β3-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in theβ 3-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the β3-AR although both compounds increase β3-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.
IGF-1 Peptides: include IGF-1 LR3 and IGF-1e (also known as MGF or Mechano Growth Factor). IGF-1 is responsible for many of the positive effects of GH on fat loss and muscle building therefore they offer a good addition, especially if your goal is to build muscle, as they are both responsible for creating new muscle cells which can hypertrophy (get bigger) through weight training.
A NOTE ABOUT RELEVANT ADVERTISING: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. This is also known as Online Behavioural Advertising. You can find out more about our policy and your choices, including how to opt-out here.
Prior studies have been largely observational, and based on measurement of natriuretic peptide levels collected in individuals with random salt intake. Because natriuretic peptide levels are dependent on loading conditions, more controlled physiologic data are needed. Accordingly, the aim of the current investigation was to study the natriuretic peptide axis in the context of a well‐controlled physiologic stimulus (intravenous saline infusion) in obese, otherwise healthy, individuals. This study design also enabled us to compare the relative effects of weight loss and intravenous saline infusion on circulating natriuretic peptide levels.
These segments of the synthetic peptide AOD9604 have been researched for their in vivo effects in laboratory mice musculus. Results have shown that AOD9604 have resulted to a short-period increase in blood glucose and a more sustained increase in plasma insulin, together with other fragments such as 172-191, 177-191 and 178-191. In addition, the researchers have suggested that functionality of the peptide depends not only in the informational sequence but should also have the correct physical configuration (Ng and Borstein 1978). Also, AOD9604, being a region of high accessibility to proteases and also rich in proline, have been demonstrated to affect the conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein by serving as the hinge for the pivoting of the two subdomains. This then suggest that such residue is significant in conformational changes be serving as sites for peripheral protein binding in some body cells (Low et al. 1984).
IGF-1 Peptides: include IGF-1 LR3 and IGF-1e (also known as MGF or Mechano Growth Factor). IGF-1 is responsible for many of the positive effects of GH on fat loss and muscle building therefore they offer a good addition, especially if your goal is to build muscle, as they are both responsible for creating new muscle cells which can hypertrophy (get bigger) through weight training.
Another way GH helps with fat loss is that it maintains blood glucose levels by inhibiting glucose uptake into peripheral cells, decreasing glucose oxidation for energy in the cells, and therefore increasing glucose production in cells from fat and amino acids (gluconeogenesis) (Copeland 1994, Ho 1996). The free fatty acids in the blood from lipolysis also partially block the insulin receptors on cell membranes, decreasing the effectiveness of insulin in triggering the removal of glucose from the blood, causing insulin resistance, or decreased insulin sensitivity. These all result in fat loss, especially from hard to move intra-abdominal fat stores (Johannsson 1997).

Nevertheless, the hypothesis that AOD9604 does not activate the hGH/IGF-1 axis had to be tested in humans. The studies presented here confirm the in-vitro results. In these studies no clinically relevant changes of IGF-1 levels were observed and no differences to the placebo treatment were found. Together with the lack of any other symptoms associated with known IGF-1 mediated effects, such as sodium retention, tissue oedema, hypertension, or impaired glucose tolerance, the results demonstrate that AOD9604 does not activate the hGH/IGF-1 pathway and therefore has no growth promoting effect.
All studies were performed as double-blind placebo-controlled trials with specific design adaption depending on the question that was to be answered. All, but the first, were performed on obese, but otherwise healthy, adults. In the first 4 studies, only male subjects were included (supplementary data). Approximately 900 adult subjects participated in these 6 clinical trials.
Growth Hormone Releasing Peptides (GHRP) are a class of compounds, which stimulate the release of growth hormone. GHRP variants include GHRP-2, GHRP-6, hexarelin, ipamorelin (Thomas et al, 2011) and agents with similar actions including CJC-1295 (Teichman et al, 2006, Acherman et al, 1999, Walker et al, 2006). These agents are considered peptide hormones. GHRPs are thought to act by stimulating the release of endogenous human growth hormone leading to pharmacological effects such as increased bone mineral density, increased lean muscle mass, modest improvements in strength and improved recovery from injuries such as fractures (Smith, 2005).
Ipamorelin is very similar to the growth hormone releasing peptides (GHRPs) GHRP 2 and GHRP 6 in that it mimics ghrelin (the hunger hormone) and targets a specific HGH pulse. However, unlike other GHRPs, this peptide doesn’t affect the release of cortisol, acetylcholine, prolactin and aldosterone thereby minimizing side effects experienced with other GH therapies, such as increased hunger. Because there are virtually no negative side effects, Ipamorelin can be prescribed more aggressively and more frequently than other therapies without the risk of elevated cortisol and acetylcholine blood plasma levels. This helps optimize HGH levels for a longer period of time, leading to more successful health outcomes.
Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.
Aging often comes with many undesirable effects on our bodies including increased fat, decreased muscle muscle mass and low energy.  Some of these issues can be caused by adult growth hormone deficiency.  Peptide therapies provide a healthy option to reinvigorate the natural release of growth hormone in the body and reverse the negative effects of aging.
The final study involved an assessment of the acute effect of AOD9604 and a β3-AR agonist (BRL37344) on energy expenditure, fat oxidation, and glucose oxidation in WT andβ 3-KO mice. When AOD9604 or BRL37344 were administered to WT mice, an acute increase in fat oxidation and energy expenditure occurred, with an associated reduction in glucose oxidation (Fig. 6A). The effect plateaued 18 min following injection and remained stable for the duration of the experiment. The response to the two compounds was very similar, despite the fact we have previously shown that AOD9604 does not directly interact with the β3-AR as demonstrated by ligand binding studies (11). This clear separation of pathways was further confirmed in Fig. 6B in which AOD9604 clearly increases fat oxidation and energy expenditure inβ 3-KO mice, whereas BRL37344 does not. The KO mice neither decrease their glucose oxidation in response to AOD9604 nor show a prolonged increase in fat oxidation and energy expenditure in response to AOD9604.
There are two types of fat in your body. The first type is visceral fat, which provides short-term energy storage. Visceral fat is located in the abdomen, situated around your vital organs. The second type is subcutaneous fat, which your body uses for long-term energy storage. Subcutaneous fat is located all over your body. Generally, 90% of the fat in the human body is subcutaneous. Women typically have a higher percentage of subcutaneous fat as opposed to men, who typically carry more visceral fat. Regardless of sex, however, this subcutaneous fat is the “stubborn” fat that is hard to lose with diet and exercise. Subcutaneous fat is the same as the “stored fat”, which is what HCG metabolises.

There are two types of fat in your body. The first type is visceral fat, which provides short-term energy storage. Visceral fat is located in the abdomen, situated around your vital organs. The second type is subcutaneous fat, which your body uses for long-term energy storage. Subcutaneous fat is located all over your body. Generally, 90% of the fat in the human body is subcutaneous. Women typically have a higher percentage of subcutaneous fat as opposed to men, who typically carry more visceral fat. Regardless of sex, however, this subcutaneous fat is the “stubborn” fat that is hard to lose with diet and exercise. Subcutaneous fat is the same as the “stored fat”, which is what HCG metabolises.
Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.
If you are interested in order a product you will need to fill out our quick 2-minute Medical Questionnaire. As we provide Schedule 4 medication we require your medical details so our Prescribing Doctor can provide you with the safest and most effective solution for your health and fitness goals. If you have any further questions surrounding our Order Process please feel free to call out Customer Support team to discuss any concerns.

Phenylephrine is a direct alpha-1 adrenergic agonist, with weak alpha-2 adrenergic agonist activity. It also has very weak beta-adrenergic effects, but at therapeutic doses there are no significant stimulating beta-1 adrenergic effects on the heart, or on the bronchial airways, or on peripheral blood vessels. This contrasts with pseudoephedrine, which has greater beta-adrenergic activity. The effect on the alpha-adrenergic receptors leads to local vasoconstriction and shrinking of mucous membranes. There is no anti-histamine effect. The drug is readily and completely absorbed following oral administration, undergoing extensive first pass metabolism in the intestinal wall and in the liver leading to some variability in individual pharmacokinetics. Nasal decongestion is apparent within 15 to 20 minutes and persists for up to 4 hours (AHFS 2007).
GHRP + GHRH (twice per day) ◦Inject your GHRP + GHRH peptides together in the same syringe (ensuring you have not consumed any food/beverages for at least 1 hour before, an optimal time would be first thing in the morning). ◦Ingest a protein only or protein and carbohydrate meal afterward to create an insulin spike. ◦Do weight training in the hours afterwards. ◦at least 1 hour after your dinner (or last meal of the day), take your second GHRP + GHRH injection. ◦If you are trying to control your body fat then have a protein only meal 20-30 minutes afterwards, otherwise a protein/carbohydrate meal will create a better insulin spike.
Five public submissions were received. Many of the submissions referred to the article published in the New England Journal of Medicine (NEJM) when giving their reasons for either supporting or rejecting the proposal. Some submissions also noted that a similar proposal is to be considered by an upcoming meeting of the Medicines Classification Committee (MCC) in New Zealand.

As we offer Schedule 4 medication we require your medical details so our Prescribing Doctor can provide you with the safest and most effective solution for your health and fitness goals. If you are interested in order a product you will need to fill out our quick 2-minute Medical Questionnaire. If you have any further questions surrounding our Order Process please feel free to call out Customer Support team to discuss any concerns.


An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
ASADA gave advice to the ACC, and perhaps Essendon, that AOD-9604 was not banned under the S2 category. Given the expectation that AOD-9604 would not be anabolic because it lacked the ''anabolic region'' of HGH, it is perhaps understandable that ASADA did not classify it under S2 in 2011 and 2012, although its close structural relationship to the banned HGH should have been sufficient to include it on the banned list.
GHRP + GHRH (twice per day) ◦Inject your GHRP + GHRH peptides together in the same syringe (ensuring you have not consumed any food/beverages for at least 1 hour before, an optimal time would be first thing in the morning). ◦Ingest a protein only or protein and carbohydrate meal afterward to create an insulin spike. ◦Do weight training in the hours afterwards. ◦at least 1 hour after your dinner (or last meal of the day), take your second GHRP + GHRH injection. ◦If you are trying to control your body fat then have a protein only meal 20-30 minutes afterwards, otherwise a protein/carbohydrate meal will create a better insulin spike.
Some athletes and bodybuilders help their body with the weight loss process using peptides like GHRP-2, a growth hormone releasing peptide. GHRP-2 has been shown to increase bone density and cellular repair, increase lean body mass, decrease body fat, and improve sleep. Combined with a reduced calorie diet and exercise program, GHRP-2 can help you achieve your weight loss and fitness goals faster.

An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.
IGF-1 Peptides: include IGF-1 LR3 and IGF-1e (also known as MGF or Mechano Growth Factor). IGF-1 is responsible for many of the positive effects of GH on fat loss and muscle building therefore they offer a good addition, especially if your goal is to build muscle, as they are both responsible for creating new muscle cells which can hypertrophy (get bigger) through weight training.
Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.
Paracetamol is distinct from non-steroidal anti-inflammatory drugs (NSAIDs). It is a para-acetylaminophenol with both analgesic and antipyretic properties. Originally synthesized in the 1880s and first released for use on prescription in 1955 in the USA and on 1956 in UK. It has been available in most countries, without prescription, for many years. Recent data suggests it acts via a central mechanism, whereby it is deacetylated to 4-aminophenyl and then conjugated with arachidonic acid to form N-arachidonoylphenylamine which is an exogenous cannabinoid (Hogestatt ED et al. 2005).
Our Doctor is available for consultations by appointment and can be made by contacting the support team. Our consultation, advice and support is 100% obligation free. All of our Peptides are prescribed by experienced Anti Ageing Doctors. They are then compounded at one of our Australian pharmacies and then shipped Australia wide to Brisbane, Sydney, Melbourne, Hobart, Adelaide, Darwin, Perth and all regional areas.

•If injecting just a GHRP or GHRH product on their own, avoid eating/drinking anything high in fat for 3 hours before your injection and anything high in carbohydrates for 2 hours before (i.e. always do your injection on an empty stomach), otherwise the amount of GH release they cause may be significantly blunted leading to poor results. •If injecting both a GHRP and GHRH together (e.g. 100mcg of both GHRP-6 and Modified GRF 1-29) studies have proven that their ability to release GH returns to full-strength as little as 1 hour (60 minutes) post-meal. This gives users greater flexibility with their meal timings, especially since consuming sufficient calories is so critical to building muscle. •Whether injecting GH peptides alone or along with others, always wait at least 20 minutes after your injection before consuming anything. Once at least 20 minutes has passed, consume a food/beverage high in protein and/or carbohydrates to stimulate an insulin spike (if you inject in the morning and around your workout, this meal/shake should be high protein and high carbohydrates, if you inject at night this consumption should be protein only as protein is sufficient enough to spike insulin, but without the negative impact on fat gain which carbohydrates can contribute to).
The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.

Up to the date of this paper, six clinical trials (three single dose studies and three multiple dose studies from which 2 were long-term studies) have been conducted with AOD9604. In none of the three acute dose-escalating studies (METAOD001 - METAOD003) were there reported any AEs related to the intake of AOD9604, withdrawals from the study caused by AOD9604 or SAEs reported. No treatment related differences were identified upon administration of AOD9604 by IV injection (25 µg - 400 µg/kg bodyweight) or orally (9 mg - 54 mg). Treatment with AOD9604 as a single dosage had no effect on physical examination, vital signs, laboratory parameters, ECG, blood glucose and IGF-1 levels, with results indistinguishable from placebo.
Perhaps. As Dr Larkins weighs in: "It's a different kind of chemical and physiological manipulation that goes way beyond what I'd call conventional hormone therapy. It's the next stage of technology that's come along to try and help people enjoy quality of life." A stage with an effect apparently significant enough to risk a professional athletic career for.
×